Enabling preventive healthcare
1 in 2 adults with type 2 diabetes will develop kidney disease, often diagnosed at stage 3 or later, which may lead to serious treatments like dialysis or kidney transplantation
The blood test for patients with type 2 diabetes to manage their risk of CKD before symptoms appear.
Identification of high risk individuals with diabetes
Proactive testing of individuals with type 2 diabetes allows the identification of people with a high-risk of developing kidney disease within the next four years
Personalised treatment
Personalisation of treatment plans based on risk of kidney decline can change clinical outcomes for both patient and healthcare system
Preventive measures
Preventive measures can be implemented before damage occurs. KDIGO guidelines recommend the use of SGLT2 inhibitors in people with diabetes to reduce risk of kidney decline
Routine CKD risk patient monitoring
Increase patient monitoring and management of kidney disease
Current Tests for CKD are just not good enough
Clinical Utility
Using the test results – 400 US-based endocrinologists & primary care physicians were surveyed on the application of test results into their clinical practice.
- 96% of physicians were likely to use PromarkerD test score for clinical decision-making
- PromarkerD consistently ranked as one of the top 2 factors driving physician decision-making
eGFR and uACR tests are reactive, not predictive of CKD
- Current standard-of-care tests are unable to predict the onset of diabetic kidney disease
- If unchecked, the individual may ultimately require dialysis and/or a kidney transplant
Early detection can help prevent serious kidney damage
- Early stage chronic kidney disease can be treated through dietary changes, lifestyle modifications and blood pressure controlling drugs, all of which ensure a relatively better quality of life
- Sodium-glucose cotransporter-2 inhibitors (SGLT2) are FDA-approved medications used for glycaemic control in diabetes
- More recently, their approval has been extended to treating CKD, making them an promising therapeutic intervention for high-risk patients identified by PromarkerD
FAQs
Who can be screened with PromarkerD?
PromarkerD has been developed and validated for the identification of adult patients with type 2 diabetes which are at increased risk of experiencing kidney function decline in the next 4 years. PromarkerD predicts the risk of otherwise healthy patients developing incident diabetic kidney disease (eGFR <60 ml/min/1.73m2). If the patient’s eGFR level at the time of the test is already <60 ml/min/1.73m2, then the risk of further kidney decline (defined as eGFR decline ≥40%) is provided.
How do I screen my patients with PromarkerD?
PromarkerD is now available in Australia and will be rolled out to other countries soon.
Please contact us to schedule a time to discuss onboarding PromarkerD in your practice.
When will screenings be available?
Please contact us directly to find out when you can access the PromarkerD test for your patients in your specific country/region.
What can be done for patients identified as at-risk by PromarkerD?
PromarkerD allows patients and healthcare providers to implement preventative measures before kidney damage occurs. Patients with elevated PromarkerD risk scores may benefit from a personalised management and/or intervention plan. Depending on the patient risk score, this may include optimisation of lifestyle factors, review of glycaemic targets and management, review of non-glycaemic risk factors and their management including blood pressure and lipids, avoidance of potentially nephrotoxic drugs, and utilisation of therapeutic drugs with evidence of renoprotection.
How does PromarkerD work and what does it measure?
PromarkerD is a prognostic blood test for diabetic kidney disease based on the measurement of novel plasma protein biomarkers using a standard immunoassay (ELISA) platform. The biomarker concentrations are combined with clinical factors. The combined raw data is submitted to the PromarkerD Hub, and a test report with the patient risk score (0-100) and risk category (low-, moderate-, or high-risk) is generated. This risk prediction is concerned with the trajectory of the patientsʼ eGFR over 4 years. A rapidly declining eGFR is one of the strongest indicators of significant renal problems and the progression of diabetic kidney disease.
How accurate is PromarkerD in predicting kidney disease risk?
The prognostic utility of PromarkerD has been validated in several clinical studies across multiple patient cohorts. In type 2 diabetes, PromarkerD accurately predicted 86% of patients who, despite having no baseline kidney impairment, developed diabetic kidney disease (DKD) within four years.
How long does it take to receive PromarkerD test results?
The PromarkerD test result will be available within 14 days of patient testing.
Do my patients still need regular kidney function tests if they use PromarkerD?
Yes, regular kidney function tests, such as eGFR and uACR, are still important even if your patients use PromarkerD. PromarkerD is a powerful tool for predicting future kidney disease risk, which complements standard kidney function monitoring. Regular tests help track current kidney health, while PromarkerD provides insights into potential future decline, allowing for more proactive and personalised management of kidney health.
Take the next step to proactive diabetes care
Bring the power of early kidney disease detection to your practice. The novel PromarkerD blood test helps you identify patients who are at risk of developing disease, empowering you to deliver personalised, preventative care.
